MNOV vs. NMRA, KALV, AURA, ORGO, ETON, VALN, PRME, KRRO, RGNX, and CTNM
Should you be buying MediciNova stock or one of its competitors? The main competitors of MediciNova include Neumora Therapeutics (NMRA), KalVista Pharmaceuticals (KALV), Aura Biosciences (AURA), Organogenesis (ORGO), Eton Pharmaceuticals (ETON), Valneva (VALN), Prime Medicine (PRME), Korro Bio (KRRO), REGENXBIO (RGNX), and Contineum Therapeutics (CTNM). These companies are all part of the "pharmaceutical products" industry.
MediciNova vs.
Neumora Therapeutics (NASDAQ:NMRA) and MediciNova (NASDAQ:MNOV) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their earnings, community ranking, media sentiment, profitability, risk, analyst recommendations, dividends, institutional ownership and valuation.
MediciNova's return on equity of -17.55% beat Neumora Therapeutics' return on equity.
In the previous week, Neumora Therapeutics had 2 more articles in the media than MediciNova. MarketBeat recorded 4 mentions for Neumora Therapeutics and 2 mentions for MediciNova. Neumora Therapeutics' average media sentiment score of 0.06 beat MediciNova's score of 0.00 indicating that Neumora Therapeutics is being referred to more favorably in the media.
MediciNova received 185 more outperform votes than Neumora Therapeutics when rated by MarketBeat users. However, 89.29% of users gave Neumora Therapeutics an outperform vote while only 48.39% of users gave MediciNova an outperform vote.
Neumora Therapeutics presently has a consensus price target of $16.50, suggesting a potential upside of 704.88%. MediciNova has a consensus price target of $9.00, suggesting a potential upside of 391.80%. Given Neumora Therapeutics' higher probable upside, analysts clearly believe Neumora Therapeutics is more favorable than MediciNova.
Neumora Therapeutics has a beta of 2.71, meaning that its stock price is 171% more volatile than the S&P 500. Comparatively, MediciNova has a beta of 0.84, meaning that its stock price is 16% less volatile than the S&P 500.
MediciNova has higher revenue and earnings than Neumora Therapeutics. MediciNova is trading at a lower price-to-earnings ratio than Neumora Therapeutics, indicating that it is currently the more affordable of the two stocks.
47.7% of Neumora Therapeutics shares are held by institutional investors. Comparatively, 9.9% of MediciNova shares are held by institutional investors. 26.4% of Neumora Therapeutics shares are held by insiders. Comparatively, 14.9% of MediciNova shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.
Summary
Neumora Therapeutics beats MediciNova on 9 of the 16 factors compared between the two stocks.
Get MediciNova News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNOV and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
MediciNova Competitors List
Related Companies and Tools
This page (NASDAQ:MNOV) was last updated on 1/21/2025 by MarketBeat.com Staff
